Page last updated: 2024-11-08

desoxyepothilone b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desoxyepothilone B: microtubule-targeted antitumor agent; lacking the epoxide of epothilone B; may be equiv to epothilone D [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

epothilone D : An epithilone that is epithilone C in which the hydrogen at position 13 of the oxacyclohexadec-13-ene-2,6-dione macrocycle has been replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID447865
CHEMBL ID96172
CHEBI ID29579
SCHEMBL ID4415
MeSH IDM0294240

Synonyms (59)

Synonym
chebi:29579 ,
12,13-desoxyepothilone b, cis
R1492 ,
CHEMBL96172
HY-15278
(4s-(4r*,8r*,9r*,13z,16r*(e)))-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)oxacyclohexadec-13-ene-2,6-dione
nsc-703147
12,13-desoxy-epothilone b
kos-862
(-)-desoxyepothilone b
depob
nsc-721085
biologically synthesized epothilone d
z-12,13-desoxyepothilone b
nsc721085
(-)-epothilone d
12,13-deoxyepothilone b
oxacyclohexadec-13-ene-2,6-dione, 4,6-dihydroxy-5,5,7,9,13-pentamethyl-16-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (4s,7r,8s,9s,13z,16s)-
nsc 703147
oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (4s-(4r*,7s,8r*,9r*,13z,16r*(e)))-
EPD ,
epothilone d
desoxyepothilone b
189453-10-9
DB01873
12,13-desoxyepothilone b
kos 862
nsc703147
LMPK04000001
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
epothiolone d
unii-t0358e0yuf
epothilone b, desoxy
kos862
t0358e0yuf ,
depob cpd
epothilon d
CS-0655
epo d
AM81237
oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4s,7r,8s,9s,13z,16s)-
SCHEMBL4415
oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (4s,7r,8s,9s,13z,16s)-
epothilone d [who-dd]
epothilone d [mi]
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-methyl-2-(2-methylthiazol-4-yl)vinyl]-1-oxacyclohexadec-13-ene-2,6-dione
XOZIUKBZLSUILX-GIQCAXHBSA-N
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]oxacyclohexadec-13-ene-2,6-dione
(4s,7r,8s,9s,16s,z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((e)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)oxacyclohexadec-13-ene-2,6-dione
AC-22616
AKOS025401598
EX-A495
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl-oxacyclohexadec-13-ene-2,6-dione
mfcd27976357
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]oxacyclohexadec-13-ene-2,6-dione
DTXSID70880053
epothilone-d
desoxyepothilone b; (3s,7s,14s,15s,16r)-3,15-dihydroxy-2,2,10,14,16-pentamethyl-7-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-6-oxacyclohexadec-9-ene-1,5-dione
A880448

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Due to its high sensitivity, specificity and simplicity, the method could be used for pharmacokinetic studies of both epothilone D and its hydrolytic metabolite."( Simultaneous determination of epothilone D and its hydrolytic metabolite in human plasma by high performance liquid chromatography-tandem mass spectrometry for pharmacokinetic studies.
Dou, G; Meng, Z; Qi, W; Sun, G; Zhang, C; Zhao, L, 2009
)
0.35
" Pharmacokinetic (PK) sampling was performed during cycles 1 and 2; pharmacodynamic (PD) assessment for microtubule bundle formation (MTBF) was performed after the 1st dose, only at or above 100 mg/m(2)."( Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Aghajanian, C; Cropp, G; Danishefsky, S; Dupont, J; Grisham, RN; Hannah, AL; Hensley, ML; Hyman, D; Johnson, R; Konner, J; Miranov, S; Mironov, S; O'Connor, OA; Park, J; Sabbatini, P; Spriggs, DR, 2012
)
0.38
" Full PK analysis (mean ± SD) at 100 mg/m(2) revealed the following: half-life (t (½)) = 9."( Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Aghajanian, C; Cropp, G; Danishefsky, S; Dupont, J; Grisham, RN; Hannah, AL; Hensley, ML; Hyman, D; Johnson, R; Konner, J; Miranov, S; Mironov, S; O'Connor, OA; Park, J; Sabbatini, P; Spriggs, DR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" This led to the identification of selected triazolopyrimidines and phenylpyrimidines that are orally bioavailable and brain-penetrant without disruption of Pgp function."( Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
Ballatore, C; Brunden, KR; Cornec, AS; Gay, B; Hoye, AT; Hyde, E; James, MJ; Lee, VM; Lou, K; Smith, AB; Trojanowski, JQ; Yao, Y, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" EpoD was evaluated for its ability to compensate for tau loss-of-function in an established Tg (transgenic) mouse model, using both preventative and interventional dosing paradigms."( Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
Ballatore, C; Brunden, KR; Lee, VM; Smith, AB; Trojanowski, JQ, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
microtubule-stabilising agentAny substance that interacts with tubulin to promote polymerisation of microtubules.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
epothiloneAny member of the class of 16-membered macrolide natural products, or their analogues, normally containing a double bond or its epoxide at positions 12-13 and bearing hydroxy groups at positions 4 and 8, methyl groups at positions 5, 5, 7, and 9, an oxo group at position 6, and a 1-(2-substituted-1,3-thiazol-4-yl)prop-1-en-2-yl substituent at position 15.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.01310.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency0.01310.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID772394Stabilization of microtubule in HEK293 cells assessed as increase in acetylated alpha-tubulin at 100 nM after 4 hrs by ELISA2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID361147Cytotoxicity against camptothecin-resistant human CCRF-CEM cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID356491Cytotoxicity against human NCI/ADR cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID771385Cytotoxicity against human MCF7 cells after 72 hrs2013European journal of medicinal chemistry, Oct, Volume: 68Epothilone D and its 9-Methyl analogues: combinatorial syntheses, conformation, and biological activities.
AID361142Cytotoxicity against human SF268 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID361144Cytotoxicity against human HL60 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID159565Induction of polymerization of porcine brain-derived microtubule protein by 2 uM epothilone B2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID94006Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID361145Cytotoxicity against mitoxantrone-resistant human HL60 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID771383Inhibition of tubulin polymerization (unknown origin) at 5 uM2013European journal of medicinal chemistry, Oct, Volume: 68Epothilone D and its 9-Methyl analogues: combinatorial syntheses, conformation, and biological activities.
AID772388Plasma concentration in CD1 mouse at 5 mg/kg, ip administered as single dose at 16 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID356493Cytotoxicity against human NCI-H460 cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID1182022Inhibition of human P-glycoprotein expressed in NCI/ADR-RES cells assessed as reduction of calcein-AM transport after 20 mins by fluorescence assay2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
AID361141Cytotoxicity against human NCI/ADR-RES cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID361140Cytotoxicity against human MCF7 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID159417Concentrations required to induce 50 percent polymerization of porcine brain-derived micro-tubule protein2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID361143Cytotoxicity against human NCI-H460 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID361146Cytotoxicity against human CCRF-CEM cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID1182021Induction of microtubule stabilization in human QBI293 cells assessed as increase in acetylated alpha-tubulin at 100 nM after 4 hrs by immunofluorescence assay relative to control2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
AID356712Cytotoxicity against mouse L929 cells2001Journal of natural products, Jul, Volume: 64, Issue:7
New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies.
AID772387Drug uptake in CD1 mouse brain at 5 mg/kg, ip administered as single dose at 16 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID356490Cytotoxicity against human MCF7 cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID772391Plasma concentration in CD1 mouse at 5 mg/kg, ip administered as single dose at 4 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID356492Cytotoxicity against human SF268 cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID772395Stabilization of microtubule in HEK293 cells assessed as increase in acetylated alpha-tubulin after 4 hrs by ELISA2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID772386Drug uptake in CD1 mouse brain at 5 mg/kg, ip administered as single dose at 4 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID94043Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (98)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (2.04)18.2507
2000's52 (53.06)29.6817
2010's35 (35.71)24.3611
2020's9 (9.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.48 (24.57)
Research Supply Index4.63 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (3.03%)5.53%
Reviews15 (15.15%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other81 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label Study to Evaluate the Effect of Combination Therapy With Epothilone D and Herceptin on Tumor Response in Patients With HER-2 Overexpressing Locally Advanced or Metastatic Breast Cancer [NCT00337649]Phase 1/Phase 227 participants (Actual)Interventional2004-05-31Completed
A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic Colorectal Carcinoma (CRC) [NCT00077259]Phase 20 participants Interventional2003-10-31Completed
A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease [NCT00104130]Phase 253 participants Interventional2004-12-31Terminated
A Phase II Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease [NCT00081107]Phase 20 participants Interventional2003-12-31Completed
A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease [NCT00080509]Phase 285 participants Interventional2003-12-31Terminated
A Phase 1, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Epothilone D in Patients With Advanced Solid Tumors [NCT00030173]Phase 145 participants Interventional2001-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]